ECM
AXSM icon

Element Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Element Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-61,510
Closed -$338K – 68
2017
Q2 		$338K Buy
+61,510
New +$257K 0.07% 63

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Element Capital Management's AXSM Position: Q3 2017 in Review

Element Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2017, closing a stake of 61,510 shares — an estimated $338K sold.

Element Capital Management first reported a position in AXSM in Q2 2017 and held it in 1 quarter. The position peaked at $338K in Q2 2017. 30 funds tracked by Wall St. Rank hold AXSM as of Q3 2017.

  • Element Capital Management reported no remaining Axsome Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 61,510 Axsome Therapeutics shares in Q3 2017, an estimated $338K.
  • Element Capital Management first reported a position in Axsome Therapeutics in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Axsome Therapeutics position peaked at $338K in Q2 2017.
  • 30 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.